Skip to main content
. Author manuscript; available in PMC: 2023 Oct 1.
Published in final edited form as: Semin Arthritis Rheum. 2022 Jun 28;56:152056. doi: 10.1016/j.semarthrit.2022.152056

Figure 2.

Figure 2.

Pretreatment plasma metabolites as potential discriminatory biomarkers of MTX response at 16 weeks. Performance of pretreatment plasma metabolite levels based on MTX response at 16 weeks by univariate analysis for nornicotine, N-methylisoleucine, 2,3-dihydroxybutanoic acid, and by multivariate analysis using a combination pseudo-score (marker-panel). Receiver operating characteristic (ROC) curves and the Youden-optimal operating points are illustrated (right panel). For each biomarker, or combination, the distribution (box-plots and actual scores) along with the Youden-based optimal cutoff is illustrated on the left panel.